Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06574269 · ClinicalTrials.gov registry record · Phase 2
A Study on TLC590 for Managing Postsurgical Pain
A Phase 2 study of Postsurgical Pain Management, sponsored by TLC Biopharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT06574269 is a Phase 2 study of Postsurgical Pain Management that is actively recruiting participants, run by TLC Biopharmaceuticals. The registered enrollment target is 120 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06574269, a Phase 2 study of Postsurgical Pain Management, is actively recruiting participants, sponsored by TLC Biopharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to ropivacaine injection.
Conditions Studied
Interventions
- DRUG TLC590
Study Locations (2)
Texas
- First Surgical Hospital - Bellaire
- Memorial Hermann Village - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06574269
The ClinicalTrials.gov registry entry for NCT06574269 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TLC Biopharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postsurgical Pain Management appearing as the primary indexed condition, and to 1 intervention - of which TLC590 is the first listed.
NCT06574269 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06574269 about?
NCT06574269 is a clinical study titled "A Study on TLC590 for Managing Postsurgical Pain". This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunio...
What is the current status of trial NCT06574269?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-09-30. Estimated completion is 2026-08.
What conditions does trial NCT06574269 study?
This clinical trial studies the following conditions: Postsurgical Pain Management.
What interventions are being tested in trial NCT06574269?
The interventions under investigation include: TLC590 (DRUG).
Who is sponsoring clinical trial NCT06574269?
This trial is sponsored by TLC Biopharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06574269 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postsurgical Pain Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.